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The ATP-sensitive potassium (KATP) channel directly regulates the microglia-mediated 
inflammatory response following CNS injury. To determine the putative role of the KATP 
channel in amyotrophic lateral sclerosis (ALS) pathology, we investigated whether ALS 
induces changes in KATP channel expression in the spinal cord and motor cortex. We 
also characterized new functional variants of human ABCC8, ABCC9, KCNJ8 and 
KCNJ11 genes encoding for the KATP channel, and analyzed their association with ALS 
risk, rate of progression and survival in a Spanish ALS cohort. The expression of 
ABCC8 and KCNJ8 genes was enhanced in the spinal cord of ALS samples, and 
KCNJ11 increased in motor cortex of ALS samples, as determined by real-time 
polymerase chain reaction. We then sequenced the exons and regulatory regions of 
KATP channel genes from a subset of 28 ALS patients and identified 50 new genetic 
variants. For the case-control association analysis, we genotyped five selected 
polymorphisms with predicted functional relevance in 185 Spanish ALS (134 spinal 
ALS and 51 bulbar ALS) patients and 493 controls. We found that bulbar ALS patients 
presenting the G/G genotype of the rs4148646 variant of ABCC8 and the T/T genotype 
of the rs5219 variant of KCNJ11 survived longer that other ALS patients presenting 
other genotypes. Also, the C/C genotype of the rs4148642 variant of ABCC8 and the 
T/C genotype of the rs148416760 variant of ABCC9 modified the progression rate in 
spinal ALS patients. Our results suggest that the KATP channel plays a role in the 
pathophysiological mechanisms of ALS. 
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Amyotrophic lateral sclerosis (ALS) is a motor neuron disease whose etiology and 
progression are not clearly understood. ALS is a multisystem neurodegenerative 
disease with heterogeneous clinical presentations [1, 2]. As a general ALS pathological 
hallmark, the loss of specific neurons in the spinal cord (motor neurons from the 
corticospinal, spinal or bulbar regions), motor cortex, and brainstem results in muscle 
atrophy and paralysis [3]. However the sensory, cerebellar, extrapyramidal, and 
autonomic systems are also affected [4]. As a reflection of the large phenotypic 
variability of ALS, about 45% of ALS patients present moderate cognitive deficits and 
another 20% of them also develop frontotemporal dementia [5, 6].  
The factors accounting for these different disease courses remain unknown. Among all 
the pathological mechanisms proposed as possible explanations for ALS 
heterogeneity, neuroinflammation is one of the few common mechanisms present in 
most ALS patients [7, 8]. The microglial reaction is associated with degenerating motor 
neurons in the ventral horn of the spinal cord, corticospinal tract and motor cortex [9]. 
Activated microglia release pro-inflammatory, neurotoxic and neurotrophic factors that 
stimulate astrocytes and recruit immune cells from the periphery [10], triggering a 
chronic inflammatory process. At the molecular level, the nature of neuroinflammation 
in ALS is heterogeneous. The phenotype of reactive microglia depends at each 
moment on a plethora of signals from the microenvironment, which in turn vary with the 
time and intensity of motor neuron damage [11]. This spectrum of microglial 
phenotypes determines the neuroinflammatory process and interferes with ALS 
progression [8]. Endogenous factors that modulate the microglial response to those 
signals may therefore account, at least in part, for the different ALS progression rates 
and patient survival.  
The ATP-sensitive potassium (KATP) channel directly regulates microglial activity and is 
a major component of the inflammatory response following CNS injury [12–16]. First 
detected in cardiomyocytes, the KATP channel is also expressed by other cell types 
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such as pancreatic β-cells and neurons from various brain regions, where it controls 
important cellular processes by coupling the electrical activity of the cell to its energy 
availability [17, 18]. Surveillant microglia show low KATP channel expression in the 
human and rodent CNS, whereas expression is increased in activated microglia in 
Alzheimer’s disease patients, rats suffering hypoxia-ischemia and mice with 
experimental autoimmune encephalomyelitis [19–21]. In reactive microglia, the KATP 
channel regulates the reactive state of the cell, controls the release of inflammatory 
compounds and modifies the phagocytic activity [22, 23]. Pharmacological activation of 
the KATP channel is neuroprotective and has anti-inflammatory effects in experimental 
autoimmune encephalomyelitis [15, 21]. It also curtails neuroinflammation associated 
with excitotoxicity, ischemia, trauma and neurotoxicant exposure [24–26]. 
The KATP channel is a large hetero-octameric protein complex comprising four 
regulatory and four pore-forming subunits. Sulfonylurea receptor (SUR) 1 and 2 
constitute the regulatory subunits of the channel and are encoded by the ABCC8 and 
ABCC9 genes respectively. The inwardly rectifying potassium channel (Kir) subunits 
6.1 and 6.2 form the pore and are encoded by the KCNJ8 and KCNJ11 genes 
respectively [27]. Given the central role of the KATP channel in the control of cellular 
processes, it is not surprising that single nucleotide polymorphisms (SNPs) in its 
encoding genes have been associated with pathological situations. Polymorphisms in 
the ABCC8 and KCNJ11 genes have been linked to type II diabetes and with 
hyperinsulinaemic hypoglycaemia [28, 29], while functional variants in the ABCC9 gene 
have been associated with different cardiomyopathies and hypertension [30].  
In the CNS, ABCC9 gene polymorphisms have been linked to sleep disorders, 
hippocampal sclerosis of aging and depression [31–33]. To our knowledge, no 
relationship has been established between functional variants of the ABCC8, KCNJ8 
and KCNJ11 genes and any human pathology involving neuroinflammation. In this 
study we hypothesized that KATP channel expression is increased in the spinal cord and 
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motor cortex of ALS patients, and that putative functional variants of genes encoding 
for this channel may modify the rate of progression and outcome of ALS.  
 
MATERIALS AND METHODS 
Human post-mortem nervous tissue 
Human post-mortem tissue samples of motor cortex and cervical and thoracic spinal 
cord were used to assess KATP channel expression via real-time reverse transcription 
polymerase chain reaction (qRT-PCR). These samples were obtained from the 
Neurological Tissue Bank of the IDIBAPS-Biobanc, (Barcelona, Spain) according to 
European ethical guidelines and following approval by the appropriate Research Ethics 
Committee. Samples were collected at autopsy from individuals who had suffered a 
clinical history of sporadic ALS (n=6), according to the El Escorial diagnostic criteria 
[34], and from non-ALS controls (n=6). Age, sex, clinical onset of symptoms, and time 
of death were characterized in all cases (Table 1). For histology procedure, 6-µm serial 
sections were obtained from paraffin-embedded tissue samples. In these sections, 
hematoxylin-eosin staining was performed to evaluate ALS neuropathology and 
neuronal loss in motor cortex and spinal cord. Some other samples were fresh-frozen 
and stored at -80ºC for qRT-PCR analysis. 
Population and clinical data for the genetics study  
A Spanish cohort of 185 ALS patients (wALS) meeting the revised El Escorial criteria 
for ALS diagnosis was included in the genetic study. A total of 750 non-affected and 
non-related control subjects were recruited from the Spanish National DNA Bank 
(Salamanca, Spain). The control group was created from a subset of 493 randomly 
selected controls subjects, matched for age and sex, to assess the risk of disease. 
Control and ALS patients were Caucasian Spanish citizens. In all cases informed 
consent to participate in studies of genetic epidemiology was collected. Sample 
collection was conducted in accordance with European ethical guidelines and 
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supervised by the appropriate Research Ethics Committee. A control group of 147 
Caucasian individuals (46 of then of Iberian origin) with no neurodegenerative disease 
and no family history were collected from the HapMap (www.hapmap.org) and 1000 
Genomes (www.1000genomes.org) projects.  
All ALS patients were clinically characterized, monitored and followed-up on an 
quarterly basis using the homogeneous criteria of Dr. Gámez at the ALS Unit of the 
Hospital Universitari Vall d’Hebron. Sex, age at onset, initial topography and survival 
time were ascertained for each patient (Table 2). Survival time was defined as the 
period between onset of clinical symptoms and the date of the need for non-invasive 
ventilation for more than 23 h/day, the date of tracheostomy ventilation, or the date of 
death.  
ALS patients were classified according to their symptom onset as spinal (Spinal ALS) 
or bulbar (Bulbar ALS). The rate of progression of patients was determined as 
previously described [35, 36]. In brief, they were ranked according to the mean slopes 
of ALSFRS-R decline and FVC decline. Patients were then divided into three groups: 
fast progression (first tertile for ALSFRS-R and FVC values), mean progression 
(second tertile), and slow progression (third tertile).  
Real-time RT-PCR 
Total RNA from spinal cord and motor cortex samples was isolated using the TRIzol 
reagent (Invitrogen, Paisley, UK) following the manufacturer’s instructions. Real-time 
RT-PCR procedures were as previously described [24, 37]. Briefly, RT reactions were 
carried out using random primers and 2 µg of mRNA was synthesized using the First 
Strand cDNA Synthesis kit (Fermentas, St. Leon-Rot, Germany). The RT reaction was 
performed at 42°C for 60 minutes followed by an additional 5 minutes at 70°C. 
SensiFASTTM SYBR Hi-ROX One-Step mix (Bioline, UK) was used to conduct real-time 
PCR. The two-step amplification program was: 2 minutes at 95°C for denaturation and 
polymerase activation, 40 cycles of 5 seconds at 95°C for denaturation, and a final 
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extension for 1 minute at 60°C. For each target gene, the expression level was 
determined using a standard curve (efficiency between 93 to 100%) and normalized to 
the GAPD mRNA level. Reactions were performed in triplicate to reduce variability. 
Supplementary Table 1 presents the primer sequences for target genes and 
endogenous controls used in the study. The ΔΔCt method was used to analyze the 
data as described by Bookout et al. [38]. Data are presented as mean ± standard error 
of the mean (SEM). Changes in expression were analyzed using the Student’s t test. 
Homogeneity of variance was checked using Levene's test. Differences were 
considered to be significant at p< 0.05. 
DNA purification and identification of variants 
A subset of 28 subjects from the wALS cohort (Table 2) was randomly selected to 
complete sequencing of exons and regulatory regions of the four genes coding for KATP 
channel subunits: ABCC8 (SUR1 subunit), ABCC9 (SUR2 subunit), KCNJ8 (Kir6.1 
subunit) and KCNJ11 (Kir6.2 subunit). Genomic DNA was extracted from whole blood 
samples of patients using the QIAamp DNA Mini Kit (QIAGEN, USA), following the 
manufacturer’s instructions. Gene sequences were analyzed for mutations in the 
coding exons, adjacent intronic regions and regulatory promoter sequences by next 
generation sequencing (NGS). To capture the sequenced regions, specific probes 
were synthesized using the SureSelect Target Enrichment kit (Agilent). Massive 
sequencing was performed using the Genome Analyzer IIx platform (Illumina, San 
Diego, CA, USA). Genetic variants were detected using the genomic DNASTAR suite 
(Madison, WI, USA), visually confirmed using the IGV software 
(www.broadinstitute.org) and manually curated. 
Selection of functionally relevant variants and genotyping 
The frequencies of the SNPs identified in the ABCC8, ABCC9, KCNJ8, and KCNJ11 
genes by sequencing in 28 ALS cases were compared with their respective 
frequencies in Caucasian and IBS populations registered on 1000genomes and dbSNP 
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databases, using DeFinetti software (http://ihg.gsf.de/ihg/snps.html, [39]). The SNPs 
showing statistically different frequencies were selected for case-control validation. The 
DeFinetti software was also used to calculate the Hardy-Weinberg (HW) equilibrium 
and to analyze the putative association of the identified variants with the disease. False 
positives due to the multiple test analysis were corrected by the Bonferroni test and 
significant differences were assumed at p<0.0002. The SNPs with statistically 
significant differences between cases and control populations were analyzed in silico 
using the SNP Function Prediction [40] and the SNP-Nexus [41] software to predict 
changes in protein coding regions, splicing sites, and transcription factor binding sites 
in the promoter.  
Variants rs4148646, rs4148642, rs148416760, rs5219 and rs1800467 were genotyped 
in DNA samples of the wALS cohort and controls (Table 2). Genotyping was performed 
using the KASPar SNP Genotyping System (LGC Genomics, UK) according to the 
provider’s standard procedures and using the primer set described in Supplementary 
Table 2. Fluorescence was measured at 25ºC in a 7300 real time PCR System 
(Applied Bioscience, USA). Genotype calling was carried out using 7300 system SDS 
software v1.4 (Applied Bioscience, USA) and Klustercaller software (LGCgenomics, 
UK). 
Case-control statistical analysis and power 
The study design was based on a pragmatic, case-control, and retrospective clinical 
analysis with a cohort of 185 ALS patients (134 spinal ALS and 51 bulbar ALS) and a 
cohort of 493 controls (>2.5 controls per case) as previously described [35]. Selected 
variants of ABCC8, ABCC9, and KCNJ11 genotypes were used as predictors of the 
risk of suffering ALS, the age at onset, the rate of progression of symptoms, and the 
survival time.  
The HW equilibrium was calculated using Fisher’s exact test implemented in the 
SNPassoc package in R Software [42]. The odds ratio (OR) and the 95% confidence 
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interval (95% CI) were estimated using generalized linear models (for either 
quantitative or binary traits), using the SNPassoc package. Analyses were performed 
using five different inheritance models (dominant, recessive, additive, co-dominant and 
over-dominant). The SPSS software (IBM, Spain) was used to perform ordinal logistic 
regression. Analyses were adjusted by sex. P-values were corrected by a factor of 7.3 
to correct for multiple test comparisons using five different inheritance models [35, 36, 
42]. Using this criterion, the uncorrected level for statistical significance was 
established at p<0.0069. Both, uncorrected and corrected (adj-p) p-values are shown.  
Survival analysis was performed using Kaplan-Meier curves and COX multivariable 
regression (SPSS software), including all dead patients and those receiving either non-
invasive ventilation for more than 23 hours/day or ventilation by tracheostomy. Sample 
size and statistical power were calculated using Quanto software [43]. This study had a 
prior statistical power of 80% (alpha = 5%) for detecting a difference of 21 months in 
survival between groups of patients (main population survival= 53.47 ± 49.2 months, 
minor allele frequency = 0.379), and a beta of 98% (alpha = 5%) for detecting a 
difference of > 29 months. For the risk of suffering ALS, this study had a power of 80% 
(alpha = 5%) for detecting an OR > 1.45 between cases and controls.  
 
RESULTS 
KATP channel expression in the spinal cord and motor cortex of ALS cases 
Hematoxylin-eosin staining revealed typical ALS-associated pathophysiological 
features in the spinal cord and motor cortex of ALS patients. We found loss of large 
motor neurons in the anterior horns of cervical and thoracic spinal cord (Fig. 1a-d). In 
these areas, most of the surviving motor neurons were swollen and presented hyaline 
conglomerate inclusions (Fig. 1b, d); some of them also contained Bunina bodies (Fig. 
1d). We also observed cell vacuolation, spongiosis and increased glial density in the 
corticospinal tracts of ALS spinal cord samples. Motor cortex sections of ALS patients 
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contained fewer Betz cells than controls. In this area, some of the surviving Betz cells 
presented hyaline conglomerate inclusions (Fig. 1e, f). 
To analyze the effects of ALS on KATP channel expression, we used RT-PCR to 
quantify the mRNA level of every channel subunit in the spinal cord and motor cortex. 
We observed low expression of SUR1 (mean CT = 27.95 ± 1.38), SUR2 (mean CT = 
27.77 ± 1.48), and Kir6.2 (mean CT = 28.14 ± 1.70) subunits in control samples, while 
Kir6.1 subunit expression was slightly higher (mean CT = 25.24 ± 0.96). In the spinal 
cord of ALS cases, we found a significant 2.27-fold increase in SUR2 (t = 7.48, p = 
0.002) and a 1.86-fold increase in Kir6.1 (t = 3.05, p = 0.038) relative to controls. Kir6.2 
expression was 3.26-fold higher (t = 2.95, p = 0.042) in the motor cortex of ALS cases 
in comparison with controls (Fig. 1g, h). 
Identification of KATP channel genetic variants in ALS patients 
We selected DNA samples of 28 subjects from the wALS cohort for NGS analysis of 
genes coding for the KATP channel. The complete sequencing of ABCC8, ABCC9, 
KCNJ8 and KCNJ11 gene exons and regulatory regions accounted for 30,368 bp of 
sequence (Supplementary Table 3). We identified a total of 238 genetic variants in all 
four genes. Fifty of these identified variants were new; 23 of them were located in the 
ABCC8 gene, 18 in the ABCC9 gene, 5 in the KCNJ8 gene, and 4 in the KCNJ11 gene 
(Supplementary Table 4). With respect to their location, we found six new variants in 
the coding region of the ABCC8 gene (variants F6S, A4P, A977T, M1394V, L1422P, 
T1509P) involving the prediction of an alternative amino acid in the translated SUR1 
protein (Supplementary Table 4).  
Analysis of the functional consequences of the identified genetic variants revealed that 
44 known SNPs have putative effects on the sequence or expression of the coded 
proteins (Supplementary Table 5). Seventeen SNPs were located in predicted 
transcription factor binding sites in the promoters of the ABCC8, ABCC9 and KCNJ11 
genes. Also, three SNPs were located in splicing sites of the primary transcript and 
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another 14 SNPs may potentially alter the splicing process of these genes. Four known 
SNPs in the coding region produce non-synonymous changes that were predicted as 
“not damaging” to protein function. Eleven variants were located in predicted miRNA 
target sites of the primary transcript. None of the new SNPs found in the KCNJ8 gene 
were predicted to be functionally relevant. 
We selected 123 polymorphisms with a predicted functional relevance and obtained 
their allele frequencies from the dbSNPs and 1000 genomes databases. Then, we 
assessed the genetic association of these SNPs in the Spanish ALS cases and the 
European or world populations. We found significant differences in the frequency of 55 
SNPs (p<0.05) between ALS cases and either European controls of Caucasian origin 
or different ethnic groups. After multiple test correction (p<0.0002), the number of 
SNPs that differed in population frequency between ALS cases and controls was 
reduced to 18. On the basis of the functional prediction and the allele frequency 
differences between ALS cases and controls, we selected the following five variants for 
a large case-control genetic study: variants rs4148646C/G and rs4148642C/T of the 
ABCC8 gene, variant rs148416760T/C of the ABCC9 gene, and variants rs5219C/T and 
rs1800467C/G of the KCNJ11 gene. 
KATP channel gene variants and disease risk or age at onset 
We obtained the genotype of the selected polymorphisms from 185 ALS patients (134 
spinal ALS and 51 bulbar ALS) and 493 Spanish controls. All five genetic variants were 
in the HW equilibrium in all groups (p=0.20 for variant rs4148646 and p=0.72 for 
variant rs4148642 of ABCC8; p=1 for variant rs148416760 of ABCC9; and p=0.26 for 
variant rs5219 and p=0.05 for variant rs1800467 of KCNJ11). None of the selected 
variants was associated with disease risk, age at onset, or familial/sporadic origin in 
any of the analyzed groups (wALS, spinal ALS and bulbar ALS).  
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KATP channel gene variants and survival 
We performed single marker analyses associating variants in ABCC8, ABCC9, and 
KCNK11 genes with the survival time (months) of wALS, spinal ALS, and bulbar ALS 
patients. We found no association of the analyzed ABCC9 gene variants with ALS 
survival time.  
Single marker analyses of the ABCC8 s4148646 variant revealed differences in the 
survival time in bulbar ALS. Patients with the G/G genotype survived for longer (116.6 
± 38.4) than patients with the C/C (42.0 ± 11.4) and C/G (30.9 ± 3.9) genotypes under 
a recessive inheritance model (Table 3). Kaplan-Meier survival curve analysis also 
revealed differences between patients with the G/G genotype (median = 153.0 months, 
95% CI [0, 401]) and those with the C/G or C/C genotypes (median = 24.0 months, 
95% CI [14.6, 35.3]) in the bulbar ALS group under a recessive model (log Rank = 
5.551; HR = 0.25, 95% CI [0.07, 0.86], p = 0.028.) (Fig. 2a). This difference was not 
significant in wALS and spinal ALS patients. 
Single marker analyses of the rs4148642 variant under a dominant model revealed a 
tendency for differences between genotypes in bulbar ALS patients. In this case, 
patients with the C/C genotype had a shorter survival time (62.8 ± 13.7 months) than 
patients with the C/T (29.5 ± 4.5 months) or T/T (20.0 ± 2.5 months) genotypes, but the 
difference did not reach significance after multiple test correction (p = 0.024). Similar 
values were observed in the spinal ALS group under a recessive model (not shown). 
Single marker analyses associating variants in the KCNJ11 gene with survival time 
also revealed some differences in bulbar ALS, but not in wALS or spinal ALS patients. 
In bulbar ALS, patients with T/T genotype of the rs5219 variant had a longer survival 
time (100.8 ± 35.1 months) than patients with the C/C (42.0 ± 11.4 months) or C/T 
(31.3 ± 54.1 months) genotypes, under a recessive inheritance model (Table 3). 
Kaplan-Meier survival curve analysis also showed differences between patients with 
the T/T genotype (median = 153.0 months, 95% CI [0, 398]) and those with the C/T or 
C/C genotypes (median = 24.00 months, 95% CI [9.9, 38.0]) in the bulbar ALS group 
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under a recessive model (log Rank = 5.083; HR = 0.31, 95% CI [0.10, 0.91], p = 0.034) 
(Fig. 2b). 
KATP channel gene variants and progression of ALS symptoms  
We performed single marker analyses associating variants in the ABCC8, ABCC9, and 
KCNK11 genes with the rate of progression of symptoms in wALS, spinal ALS, and 
bulbar ALS patients. We found no association between the analyzed KCNJ11 gene 
variants and the progression of ALS symptoms. 
Single marker analyses of the ABCC8 rs4148642 variant revealed some differences 
between wALS and spinal ALS patients, under a dominant inheritance model (Table 4). 
In the wALS group, the frequency of the C/T and T/T genotypes (38%) was higher in 
patients showing a slow progression of ALS symptoms, compared with the wild type 
C/C genotype frequency (26.6%). In spinal ALS patients, the wild type C/C genotype 
was even more common in patients with a fast rate of progression (48,2%) than the 
C/T and T/T genotypes (16,1%). This difference that showed a significant protective 
effect in spinal ALS (OR=0.31; 95%IC [0.15 – 0.62]; p=0.001) was not significant in 
bulbar ALS patients. 
Single marker analyses of the rs148416760 variant in the ABCC9 gene also revealed 
some differences in wALS and spinal ALS patients, under a dominant inheritance 
model (Table 4). In the wALS group, 83.3% of patients with the T/C genotype showed 
a fast progression of ALS symptoms, whereas only 37.3% of patients with the T/T 
genotype showed that fast progression. In spinal ALS patients, 100% of patients with 
the T/C genotype showed fast progression of symptoms. This significant effect in spinal 







This study provides evidence that ALS increases the expression of the ABCC8 and 
KCNJ8 genes in the spinal cord and KCNJ11 in the motor cortex of patients. Moreover, 
we report for the first time on the association of the rs4148646G/G and rs5219T/T variants 
of the ABCC8 and KCNJ11 genes respectively with longer survival times in bulbar 
ALS; and on the association of the rs4148642C/C and rs148416760T/C variants of the 
ABCC8 and ABCC9 genes respectively with changes in the progression rates in spinal 
ALS patients. These results suggest a role for the KATP channel in the course of ALS, 
both by modifying the survival time and the rate of progression of symptoms.  
Due to the low number of samples and the complex regulation of translational 
mechanisms and protein synthesis, the expression changes here described by RT-
PCR are not conclusive and further experiments are needed to validate and better 
understand these different expression patterns. Nevertheless, our results may reflect 
diverse mechanisms of regulation of KATP channel expression associated with the 
control of microglial activity during ALS. The expression of ABCC8, ABCC9, KCNJ8 
and KCNJ11 increases in the CNS in several pathological situations, and has been 
associated with the molecular control of neuroinflammation [12–14, 16, 21]. For 
example, increase of astroglial ABCC9 expression in human brain samples has been 
associated with risk genotypes for hippocampal sclerosis of aging [44]. In addition, 
pharmacological activation of the KATP channel curtails the microglial reaction and 
exerts neuroprotective and anti-inflammatory effects [25, 45]. The increased 
expression of ABCC9 and KCNJ8 found in the spinal cord of ALS cases suggests the 
involvement of the KATP channel in the control of neuroinflammation processes 
associated with this disease. However the main subunits assembling functional KATP 
channels in brain microglia are encoded by ABCC8 and KCNJ11 [12, 23, 24] and in the 
motor cortex we only found increased expression of KCNJ11. Differential ALS-induced 
changes in gene expression in the motor cortex and spinal cord have already been 
described for genes such as human sirtuins [46], a protein family involved in the control 
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of neuroinflammation [47], and rat glutamate transporter 1 variants [48]. These tissue-
dependent variations in gene expression have been proposed to explain in some 
extent susceptibility of tissues to cell loss and to modify ALS progression [48].  
Genes encoding KATP channel components have been found to be highly polymorphic, 
especially the ABCC8 gene [49]. Variations in ABCC8 and KCNJ11 genes compromise 
the molecular mechanism of insulin release and have been associated with type II 
diabetes mellitus and with hyperinsulinemic hypoglycemia (see [50] for a review). Also, 
functional variants in the ABCC9 gene have been associated with different 
cardiomyopathies, hypertension [51, 52], sleep disorders, hippocampal sclerosis of 
aging and depression [31–33]. We identified 286 variants after mutational analysis of 
exons and regulatory regions of these genes in Spanish ALS patients. Forty-five of 
these variants are new; most of them located in ABCC8 and ABCC9, and could 
potentially modify the expression of these genes. Most noticeable is that five of the new 
variants found in the ABCC8 gene involve changes in the SUR1 protein sequence that 
may have functional consequences. SUR subunits of the KATP channel are the 
pharmacological target for the treatment of several pathologies. For example, 
sulfonylureas block the KATP channel by binding to SUR and are used for the treatment 
of type II diabetes [53], while potassium channel openers (KCOs) also bind to SUR, 
activate the channel and are indicated for the treatment of hypoglycemia and malignant 
hypertension [54]. The new polymorphisms herein described in the ABCC8 gene may 
thus modify the affinity of those compounds for the channel and account for differential 
drug efficacy among patients. Additional molecular and cellular experiments are 
needed to characterize the effects of these polymorphisms on KATP channel activity and 
to clarify their putative pharmacological relevance. 
Our preliminary association analysis of 123 polymorphisms in the ABCC8, ABCC9, 
KCNJ8 and KCNJ11 genes identified 18 variants with different frequency distributions 
between a Spanish ALS cohort and controls of either Caucasians or different ethnic 
groups worldwide. On the basis of their putative functional relevance, we selected five 
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of these variants for a large case-control study, but the remaining 13 polymorphisms 
may still be associated with ALS. However as these differences in genotype distribution 
may also reflect unequal allele frequencies between the Spanish cohort and the 
European or world populations, new experiments with a higher number of ALS cases 
and appropriate controls are needed to validate these associations. 
In our case-control study, the rs4148646G/G and rs5219T/T variants of ABCC8 and 
KCNJ11 respectively were associated with longer survival times in ALS patients with 
bulbar onset under a recessive genetic model. These associations were not significant 
in patients with spinal onset, which implies a role for the KATP channel in tissue 
susceptibility to cell loss and ALS pathogenesis. Three of the bulbar-onset ALS 
patients with rs4148646G/G and rs5219T/T variants of ABCC8 and KCNJ11 genes had 
mild or moderate impaired bulbar function, and upper motor neuron predominant 
involvement. Interestingly, this subgroup of bulbar ALS onset has longer median 
survivals if they are offered non-invasive mechanical ventilation [55, 56]. 
Polymorphism rs4148646 is an intron variant of the ABCC8 gene (intron 38-39) with 
unknown function and no previously described pathological association. Intronic 
polymorphisms do not vary protein sequence or function but they are proposed to 
modify gene expression or mRNA splicing processes [57]. In this context, some intronic 
variants of the ABCC8 gene have been associated with type II diabetes mellitus [29]. 
The rs4148646G/G variant of ABCC8 may hence modify the availability of SUR1, which 
is required to ensemble functional channels. It is also possible that the rs4148646G/G 
polymorphism could be a genomic marker in linkage disequilibrium with other adjacent 
functional variants. Meanwhile the rs5219 variant of KCNJ11 involves a protein 
sequence change (E23K) and has been associated with type II diabetes mellitus in 
Asian Indian and Chinese populations but not in Caucasians [29, 58–60]. The 
association of these two variants with a longer survival time in bulbar ALS patients may 
be related to the role of the KATP channel in the control of microglia-mediated 
inflammatory processes. ABCC8 and KCNJ11 encode for SUR1 and Kir6.1, which are 
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the main subunits of the functional KATP channel in microglia [12, 23, 24]. Thus, ALS 
patients harboring rs4148646G/G or rs5219T/T variants may present reactive microglia 
with a reduced cytotoxic profile, resulting in curtailed neuroinflammation and a less 
severe neurodegenerative process. In this context, survival time has recently been 
associated with a genetic variant of the CX3CR1 gene in sporadic ALS patients [35]. In 
the CNS, CX3CR1 encodes for a microglial receptor that mediates microglia-neuron 
interactions [61], which also implies a role for reactive microglia in ALS pathogenesis 
[8]. 
Our study also found an association between the rs4148642C/C and rs148416760T/C 
variants of the ABCC8 and ABCC9 genes respectively and changes in the rates of 
progression in spinal ALS patients but not in patients with bulbar onset. This difference 
may have clinical relevance that could help identify the patient’s risk of requiring 
gastrostomy tube feeding or mechanical ventilation. It also suggests a role for SUR 
subunits of the KATP channel in tissue susceptibility to cell loss and ALS progression. 
Polymorphism rs4148642 in the ABCC8 gene is also an intronic variant (intron 30-31), 
while the rs148416760 SNP of ABCC9 is located in the 3’-untranslated region (UTR). 
Both polymorphisms have unknown function and no previously described pathological 
association. Two intronic variants of ABCC9 have been previously associated with 
hippocampal sclerosis of aging, a pathology involving TDP-43 [32]. Due to their 
location, these variants were not genotyped in our study but they are not in linkage 
disequilibrium with the rs148416760 polymorphism in the IBS population, suggesting 
that they are not associated with the progression rate of ALS. However a large case-
control study would be necessary to validate this hypothesis. ABCC9 genetic regulation 
is complex and includes different short and long variants in the 3’-UTR region of mRNA 
[62] that may determine the translational efficiency and mRNA stability [63] and are 
proposed to be associated with pathological situations [62]. Thus, the rs4148642 and 
rs148416760 polymorphisms herein associated with the progression of ALS symptoms 
may modify the availability of SUR1 and SUR2 and thus the assembly of functional 
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KATP channels, with major consequences for the control of microglial activity and 
neuroinflammation. 
This study presents some limitations due to the low incidence of bulbar onset in the 
ALS population, and to the low allelic frequency of the rs148416760 variant of ABCC9. 
It is interesting to note that, in spite of these sample size limitations, our results reach 
statistical significance and suggest an association of the analyzed ABCC8, ABCC9 and 
KCNJ11 variants with the progression and outcome of ALS. Finally, this study opens 
new questions to be addressed in a future functional study that must include samples 
of ALS patients with different genotypes and clinical phenotypes. Thus, the relationship 
between neuroinflammation parameters and the distribution, expression and protein 
concentration of the KATP channel need to be analyzed in a larger number of samples 
from ALS patients presenting different disease onsets and genetic polymorphisms. 
In conclusion, our study reports for the first time an association of ABCC8, ABCC9 and 
KCNJ11 genetic variants with the rate of progression of symptoms and survival time of 
ALS patients, which indicates that the KATP channel plays a role in the course of the 
disease. Variants rs4148646G/G and rs4148642C/C of ABCC8, rs148416760T/C of 
ABCC9 and rs5219T/T of KCNJ11 may therefore be used as genetic markers of 
prognosis in the survival and progression of ALS. Furthermore, our study points to the 
KATP channel as a putative pharmacological target for the treatment of ALS. To validate 
these hypotheses, further experiments are needed to characterize at the molecular, 
cellular and pharmacological levels the role of the KATP channel in the control of 
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FIGURE LEGENDS  
Fig. 1. Pathophysiological features and KATP channel expression changes in spinal 
cord and motor cortex of ALS patients. (a-f) Hematoxylin-eosin staining of transverse 
sections of thoracic spinal cord (a-d) and motor cortex (e-f). Arrows mark large neurons 
with hyaline conglomerate inclusions in the anterior horn (d) and Beth cells in motor 
cortex (f). Some cells also contained Bunina bodies (arrowhead in d). Bars: 100 µm in 
a and c; 25 µm in b, d, e and f. (g, h) Graphs show the ALS-induced fold change of 
KATP channel expression quantified by qRT-PCR in the spinal cord (g) and motor cortex 
(h). ABCC8 and ABCC9 genes encode for the SUR1 and SUR2 subunits, while KCNJ8 
and KCNJ11 genes correspond to the Kir6.1 and Kir6.2 subunits respectively. 
Student’s t test; *, p < 0.05; **, p < 0.01  
 
Fig. 2. Kaplan-Meier survival curves for bulbar ALS patients with different ABCC8 and 
KCNJ11 genotypes. (a) Curves for ABCC8 rs4148646 genotypes according to a 
recessive genetic model; log Rank = 5.551; HR = 0.25, 95% CI [0.07, 0.86], p = 0.028. 
(b) Curves for KCNJ11 rs5219 genotypes according to a recessive genetic model; log 
Rank = 5.083; HR = 0.31, 95% CI [0.10, 0.91], p = 0.034. 
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Table 1. Detail of the cases included in the gene expression study. 
 Controls sALS  
Nº cases 6 6 
 Women 2 2 
 Men 4 4 
Age at onset, years (range) - 46 (34-58) 
Age at death, years (range) 61 (40-82) 58 (38-79) 
Topography  - Spinal 




Table 2. Demographic data of the subjects included in the genetic study  
 Controls wALS Spinal ALS Bulbar ALS 
Subjects* 493 (750) 185 134 51 
 Women (%) 227 (46.0%) 89 (48.1 %) 61 (45.5%) 28 (54.9%) 
 Men (%) 266 (54.0%) 96 (51.9%) 73 (54.5%) 23 (45.1%) 
Age (range) 57.8 ± 4.0 (28-99) 
60.0 ± 13.2 
(28-91) 
57.7 ± 12.7 
(28-91) 
65.8 ± 12.7 
(38-87) 
 Women** 60.9 ± 16.5 60.2 ± 12.8 58.2 ± 11.4 64.5 ± 14.8 
 Men** 55.1 ± 10.9 59.8 ± 13.6 57.4 ± 13.8 67.4 ± 9.6 
Age at onset** - 55.5 ± 13.7 53.0 ± 13.3 62.2 ± 12.6 
Age at death** - 62.0 ± 12.4 59.1 ± 12.1 67.2 ± 11.2 
Mortality - 106 (57.3%) 72 (53.7%) 34 (66.7%) 
ALS type     
 Familial - 45 32 13 
 Sporadic - 140 102 38 




Table 3. Single marker analysis for ALS patient survival time (months) according to the topography 
onset under a recessive model. 
Gene / variant Onset Genotype n Median ± SD Diff  (95% CI) p value 
ABCC8 / rs4148646      
 
wALS 
C/C-C/G 123 55.5 ± 4.6 
13.8 (-11.4, 39.1)  0.284 
 G/G 20 68.5 ± 14.4 
 
Spinal ALS 
C/C-C/G 88 63.6 ± 5.9 
-8.46 (-39.5, 22.6) 0.595 
 G/G 14 54.5 ± 13.6 
 
Bulbar ALS 
C/C-C/G 34 35.4 ± 5.2 
81.4 (42.7, 120.0) 0.0002 
 G/G 5 116.6 ± 38.4 
KCNJ11 / rs5219      
 
wALS 
C/C-C/T 122 55.3 ± 4.6 
16.7 (-8.5, 42.1) 0.196 
 T/T 20 71.2 ± 14.1 
 
Spinal ALS  
C/C-C/T 88 63.0 ± 5.9 
-1.5 (-33.8, 30.6)  0.924 
 T/T 13 61.2 ± 13.9 
 
Bulbar ALS 
C/C-C/T 33 35.8 ± 5.3 
66.0 (27.7, 104.2) 0.0017 




Table 4. Single marker analysis for rate of progression of ALS symptoms according to 
the topography onset under a dominant model. 
Gene / variant Onset Genotype 
Progression subgroup n (%) Effect compared to Fast progression 
Fast Normal Slow OR (95%IC) p value model p value 
ABCC8 / rs4148642        
 
wALS 
C/C 39 (49.4) 19 (24.1) 21 (26) 0.49 
(0.27, 0.88) 0.017 0.016  C/T + T/T 23 (29.1) 26 (32.9) 30 (38) 
 Spinal 
ALS 
C/C 27 (48.2) 14 (25) 15 (26) 0.31 
(0.15, 0.62) 0.001 0.001  C/T + T/T 9 (16.1) 21 (37.5) 26 (46) 
 Bulbar 
ALS 
C/C 10 (47.6) 5 (23.8) 6 (28,6) 1.76 
(0.56, 5.54) 0.331 0.329  C/T + T/T 14 (60.9) 5 (21.7) 4 (17,4) 
ABCC9 / rs148416760        
 
wALS 
T/T 57 (37.3) 46 (30.1) 50 (32) 7.23  
(0.92, 57.0) 0.061 0.038  T/C 5 (83.3) 0 (0) 1 (16.7) 
 Spinal 
ALS 
T/T 31 (28.7) 36 (33.3) 41 (38) 27.06 * 
(1.45, 504) <0.001 0.001  T/C 5 (100) 0 (0) 0 (0) 
 Bulbar 
ALS 
T/T 24 (55.8) 10 (23.3) 9 (20.9) 0.27 * 
(0.01, 6.88) <0.001 0.081  T/C 0 (0) 0 (0) 1 (100) 

















Supplementary Table 1 Primer sequences included in the qRT-PCR study 
Target Gene Sequence (5’-3’) Size Accesion nº 
GADP GAPD F:   GAGTCAACGGATTTGGTCGT R:   TTGATTTTGGAGGGATCTCG 238 bp NM_002046.2 
SUR1 ABCC8 F:   GTCCAGATCATGGGAGGCTA R:   CAGAAGACAGCCCCTGAGAC 182 bp NM_000352 
SUR2 ABCC9 F:   CATCCATTAGTGGGTCTTCG R:   GATGTAAGCCTTGACGTGCT 229 bp NM_020298 
Kir6.1 KCNJ8 F:   CATGGAGAAAAGTGGAATGG R:   TGGAGAATCAAAACCGTGAT 174 bp NM_004982 
Kir6.2 KCNJ11 F:   TTTTCTCCATTGAGGTCCAA R:   TTGCTGAAGATGAGGGTCTC 190 bp NM_000525 
  
 
Supplementary Table 2 Primer sequences used for genotyping of KATP channel variants 
Gene ID Allele X primer Allele Y primer Common primer Allele X 
Allele 
Y 
ABCC8_rs4148646 CAGGGACAGGACTGGCCTG CAGGGACAGGACTGGCCTC CTGTGCACTGATGACGGCCACAA G C 
ABCC8_rs4148642 CCTGGGGCTCCAGCCTTC CTCCTGGGGCTCCAGCCTTT CCACTCCAGCCCTGCAACTCAT C T 
ABCC9_rs148416760 GGCAGGCCAGCTAAACTTTCTG GGCAGGCCAGCTAAACTTTCTA GCTCAAGATCATAACCACAGCTAATCATT C T 
KCNJ11_rs5219 GGCACGGTACCTGGGCTC GGGCACGGTACCTGGGCTT ATACGTGCTGACACGCCTGGCA C T 
KCNJ11_rs1800467 CAGGTCGCTGGGTGCCAC CAGGTCGCTGGGTGCCAG TCATTGATGCCAACAGCCCACTCTA G C 
 
Supplementary Table 3 Characteristics of the gene sequences selected for NGS  
Target Gene  Number of exons 
Promoter 
(bp) 
Size of the obtained 
sequences (bp) 
SUR1 ABCC8 39 1000 9062 
SUR2 ABCC9 44 1000 11993 
Kir6.1 KCNJ8 2 1000 4746 
Kir6.2 KCNJ11 3 1000 4567 
 
 
Supplementary Table 4 Variants identified in the genomic sequence of 28 ALS patients. 
Gene Identified Variants 
New 
Variants 3’UTR 5’UTR 
Non-
synonymous  Synonymous  Promoter 
Essential 
splice site 
ABCC8 92 23 rs73419228 rs77498130 rs8192690 rs1799859 rs8192694 rs1799854 







































Gene Identified Variants 
New 
Variants 3’UTR 5’UTR 
Non-
synonymous  Synonymous  Promoter 
Essential 
splice site 











KCNJ11 21 4 rs5212   rs8175351 rs35271178  
New variants are shown in red  
 
 
Supplementary Table 5 Predicted functional consequences of the identified genetic variants according to FuncPred 




nsSNP Polyphen Disease association 
ABCC8 rs4148646 17393643 G>C Intronic -- Y -- -- -- Diabetes type 2 
ABCC8 rs4148642 17397953 C>T Intronic -- -- -- -- -- Diabetes type 2 
ABCC8 rs60824529 17453137 G>A CDS N386N -- Y N -- NA 
ABCC9 rs148416760 21800268 T>C 3’ UTR -- -- -- -- -- NA 




PPAR-γ1 -- Y Benign 
Diabetes 
type 2* 





KCNJ11 rs57778283 17390038 C>T 5’ upstream -- Y -- -- -- NA 
KCNJ11 rs57988393 17390057 A>C 5’ upstream -- Y -- -- -- NA 
NA, Non associated; *, According to PharmGx; related to GRCh38.p7 
